1. Home
  2. IRS vs COLL Comparison

IRS vs COLL Comparison

Compare IRS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRS
  • COLL
  • Stock Information
  • Founded
  • IRS 1943
  • COLL 2002
  • Country
  • IRS Argentina
  • COLL United States
  • Employees
  • IRS N/A
  • COLL N/A
  • Industry
  • IRS Homebuilding
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRS Real Estate
  • COLL Health Care
  • Exchange
  • IRS Nasdaq
  • COLL Nasdaq
  • Market Cap
  • IRS 1.2B
  • COLL 1.1B
  • IPO Year
  • IRS 1994
  • COLL 2015
  • Fundamental
  • Price
  • IRS $14.75
  • COLL $35.91
  • Analyst Decision
  • IRS
  • COLL Strong Buy
  • Analyst Count
  • IRS 0
  • COLL 4
  • Target Price
  • IRS N/A
  • COLL $44.25
  • AVG Volume (30 Days)
  • IRS 377.9K
  • COLL 319.9K
  • Earning Date
  • IRS 11-05-2025
  • COLL 11-06-2025
  • Dividend Yield
  • IRS 6.75%
  • COLL N/A
  • EPS Growth
  • IRS N/A
  • COLL N/A
  • EPS
  • IRS 0.20
  • COLL 1.06
  • Revenue
  • IRS $416,589,564.00
  • COLL $707,007,000.00
  • Revenue This Year
  • IRS N/A
  • COLL $21.29
  • Revenue Next Year
  • IRS N/A
  • COLL $3.36
  • P/E Ratio
  • IRS $6.76
  • COLL $33.77
  • Revenue Growth
  • IRS N/A
  • COLL 22.61
  • 52 Week Low
  • IRS $10.61
  • COLL $23.23
  • 52 Week High
  • IRS $17.67
  • COLL $39.95
  • Technical
  • Relative Strength Index (RSI)
  • IRS 60.35
  • COLL 57.44
  • Support Level
  • IRS $14.41
  • COLL $35.33
  • Resistance Level
  • IRS $16.05
  • COLL $36.58
  • Average True Range (ATR)
  • IRS 0.84
  • COLL 1.03
  • MACD
  • IRS 0.29
  • COLL 0.21
  • Stochastic Oscillator
  • IRS 69.79
  • COLL 81.50

About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: